You are here: Industry Insights > dMMR

News List

Eisai, Merck’s Drug Combo Approved for Advanced Endometrial Cancer contractpharma
July 26, 2021
LENVIMA plus KEYTRUDA demonstrates improvements in overall survival, reducing the risk of death by 32%, and progression-free survival by 40%.
FDA Approves Carcinoma Treatment americanpharmaceuticalreview
July 23, 2021
The FDA approved pembrolizumab (Keytruda - Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) ...
GSK’s PD-1 inhibitor Jemperli approved in the UK pharmatimes
June 08, 2021
GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer.
Opdivo plus Yervoy moves closer to EU approval for dMMR/MSI-H colorectal cancer pharmatimes
May 26, 2021
Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy combination therapy has moved closer to EU approval for certain colorectal cancer patients, after scoring a positive opinion from the European Medicines Agency’s (EMA) Committee for ...
FDA Grants Accelerated Approval to Dostarlimab-Gxly for dMMR Endometrial Cancer americanpharmaceuticalreview
April 26, 2021
The Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test ...
Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint prnasia
March 29, 2021
Shanghai Henlius Biotech, Inc. announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail to ...
Roche to develop new dMMR pan-cancer test for Merck’s Keytruda immunotherapy fiercebiotech
December 26, 2018
If you can’t beat 'em, join 'em: Roche is teaming up with its immuno-oncology competitor Merck & Co. to develop a pan-cancer companion diagnostic test for its Keytruda therapy aimed at